Summit Therapeutics Flags Going Concern Risk Over Cash Needs
Summit Therapeutics beat second-quarter estimates but warned current cash is insufficient to fund operations for the next year.
Summit Therapeutics made more money than expected this quarter, but they're warning they might run out of cash soon and won't have enough money to keep running the company for a whole year. When a company says this, it means they need to find more money fast—either by borrowing, selling more stock, or making a big deal.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.